In order to solve client concerns within the present bioanalytical workflows of Agilent Technologies, Inc. (NYSE: A), we started working with them as the biopharmaceutical industry continued to grow. In accordance with the conditions of the Agreement, a Memorandum of Understanding, Protea Biosciences has increased its cooperation with Agilent to create workflows that concentrate on fresh methods for the field of metabolomics (MOU). This partnership makes use of both Agilent technology and instrumentation.
Memorial Sloan-Kettering Cancer Center
We entered into a collaborative research initiative with the Memorial Sloan-Kettering Cancer Center (MSK) and the Dana-Farber Cancer Institute (Dana-Farber) that uses Protea’s mass spectrometry imaging (MSI) technology to analyze cancer cells. The initial focus is early stage lung adenocarcinoma. The studies will apply Protea technology to generate molecular profiles of sub populations of cancer cells in tissue to improve the understanding of a cancer’s origin
Protea entered into aco-marketing agreement with MatTek Corporation which enables Protea to include MatTek’s human cell based in vitro tissue models with Protea’s proprietarymolecular imaging services. MatTek is at the forefront of tissue engineering and is a world leader in the production of innovative 3D reconstructed human tissue models.
We entered into an exclusive license agreement with Yale University for new Mass Spectrometry Imaging (MSI) technology to improve the differential diagnosis of malignant melanoma. The technology was developed jointly by the laboratory of Rossitza Lazova, MD, Associate Professor of Dermatology and Pathology at Yale School of Medicine and Protea Biosciences.
We entered into a business collaboration with Protein Metrics Inc. a premier provider of software solutions for the comprehensive characterization of proteins, to advance our analytical capabilities for use in the development of protein biotherapeutics.
Proteos is a contract research organization located in Kalamazoo, MI that specializes in the production of high-quality research grade recombinant proteins for the pharmaceutical, biotechnology and life science communities. To learn more about Proteos’ contract research service offerings, please visit their website Proteos. Protea will be the exclusive provider of mass spectrometry services for characterization of proteins and antibodies produced by Proteos
In the future, we will expand our proprietary methods for molecular imaging and bioanalytical workflows. By bringing new developments in sample analysis and instrumentation, our capacity to provide big data to researchers will continue to advance, to meet the needs of tomorrow’s scientists for better, more comprehensive molecular information.
Focus Proteomics is a proteomics contract research organization (CRO) specializing in protein fractionation and two-dimensional gel electrophoresis (2DGE) to identify and quantify proteins and their post-translational modifications. Protea has entered into a co-marketing relationship with Focus Proteomics to provide mass spectrometry protein identification capabilities to researchers performing upstream protein fractionation or two-dimensional gel electrophoresis